Over-diagnosis of potential malignant behavior in MEN 2A-associated pheochromocytomas using the PASS and GAPP algorithms

Adam Stenman 1 · Jan Zedenius 2,3 · Carl Christofer Juhlin 1,4

Received: 8 March 2018 / Accepted: 30 April 2018 / Published online: 19 May 2018 © The Author(s) 2018

Abstract

Purpose Pheochromocytomas (PCCs) exhibit malignant potential, but current histological modalities for the proper detection of aggressive behavior are debated. The two most widespread algorithms are the “Pheochromocytoma of the Adrenal Gland Scaled Score” (PASS) and the “Grading System for Adrenal Pheochromocytoma and Paraganglioma” (GAPP), both which mostly rely on histological parameters to identify PCC patients at risk of disseminated disease. Since the algorithms are derived from studies using predominantly sporadic PCCs, little is known whether the PASS or GAPP scores can predict malignant potential in hereditary cases.

Methods PASS and GAPP were applied on 41 PCCs; 13 PCCs were diagnosed in ten multiple endocrine neoplasia type 2A (MEN 2A) patients carrying established germline RET proto-oncogene mutations, as well as 28 assumed sporadic PCCs.

Results Six out of thirteen MEN 2A tumors (46%) exhibited PASS scores ≥ 4, indicative of a potential for aggressive behavior. In addition, 7/13 tumors (54%) exhibited GAPP scores ≥ 3, indicative of a “moderately differentiated type” with risk of future recurrence. All MEN 2A PCCs with an elevated PASS score also displayed an elevated GAPP score. In contrast, 4/28 (14%) sporadic PCCs demonstrated PASS scores ≥ 4, and 9/28 (32%) displayed GAPP scores ≥ 3. Follow-up found all cases in the study are free of metastatic or recurrent disease.

Conclusions We conclude that the PASS and GAPP scoring systems might be suboptimal for determining true malignant potential in PCCs with constitutional RET mutations and advocate restrictive use of these scores in MEN 2A cases until the results are reproduced in larger numbers.

Keywords Pheochromocytoma · MEN 2A · PASS · GAPP · Malignancy

Introduction

Pheochromocytomas (PCCs) are rare endocrine tumors derived from the adrenal medulla. Although the majority of tumors are sporadic, a large subset of cases displays a hereditary background [1]. The current WHO criteria from 2017 states that all PCCs are potentially malignant and should be risk stratified using one or both of the established algorithms: the Pheochromocytoma of the Adrenal Gland Scaled Score (PASS) [2] and an alternative scoring system by Kimura et al. (the Grading System for Adrenal Pheochromocytoma and Paraganglioma (GAPP)) [3]. While PASS incorporates a scoring system including various histological parameters, the alternative scoring system GAPP extends on this and includes histological as well as immunohistochemical (Ki-67) and clinical (catecholamine phenotype) variables. When assessing malignant potential of PCCs, the PASS algorithm is probably the most widespread scoring system. A score from 0 to 20 points is acquired based on histological findings, in which tumors with a PASS score ≥ 4 have the potential for aggressive behavior. The GAPP score categorize PCCs into three different types, well-differentiated PCCs (score 0–2), moderately differentiated PCCs (score 3–6), and poorly differentiated PCCs (score ≥ 7).
PCCs (score 7–10), in which the two latter groups carry an increased risk of recurrences and future metastases.

In our institution, we have empirically noted that MEN 2A PCCs often obtain high PASS and GAPP scores. However, as MEN 2A-related PCCs (as well as PCCs with somatic \( RET \) mutations) are very seldom malignant [1], this case made us unsure as to whether the PASS and GAPP systems are applicable to this specific subset of PCCs. We therefore sought to determine the PASS and GAPP score ranges and the follow-up for PCCs with established constitutional \( RET \) mutations at our institution, to investigate whether these classification systems can predict patients at risk for malignancy in MEN 2A patients.

**Materials and methods**

We screened our clinical databases and identified 10 patients with 13 resected PCCs during the period 1987–2017, all patients harboring \( RET \) constitutional mutations (c.1900T>C in two, c.1858T>C in one, and c.1900T>G in the remaining seven patients) (Table 1). As an assumed sporadic control group, 28 unilateral PCCs diagnosed consecutively at our institution between 2011 and 2017 in patients ≥40 years of age with unknown \( RET \) mutational status but no apparent family history suggesting hereditary disease were included. No paragangliomas were included in the study. An endocrine pathologist (CCJ), blinded to clinical outcome, reviewed the original pathology reports and reviewed the histopathological characteristics of all cases using the PASS and GAPP scoring systems. To be able to fully acquire a GAPP score for each case, patient charts were reviewed for the procurement of biochemical data (catecholamine types) as well as Ki-67 indexes. Older cases without original Ki-67 data (11 MEN 2A tumors) were recut and stained with an anti-Ki-67 antibody in a clinically accredited pathology laboratory using standardized methodology. For the sporadic control group, all Ki-67 proliferation counts were retrieved from the pathology reports. The histological and biochemical results as well as clinical follow-up data for the MEN 2A cases are presented in Table 1, and examples of positive histological PASS and GAPP parameters are illustrated in Fig. 1. An Olympus BX46 microscope equipped with a ToupTek E3CMOS camera and ToupView software v. 3.7 was used for evaluation of slides and acquisition of photomicrographs. In addition, clinical follow-up of all patients was reviewed (Table 1).

**Statistical analyses**

Statistical analyses were made with IBM SPSS Statistics 24 (IBM, Armonk, NY, USA). Non-normal distribution was assumed for all data, applying the Mann-Whitney \( U \) and Fisher’s exact tests for comparison between groups. \( P \) values < 0.05 were considered as statistically significant.

**Results**

The median age was 41 for the MEN 2A group and 63.5 for the sporadic controls. The MEN 2A group consisted of 7 female and 6 male patients, whereas the sporadic controls included 16 female and 12 male patients. The majority of MEN 2A patients in this series have been followed for over 200 months and were all free of metastatic or recurrent disease (Table 1). No recurrences or metastases were observed in the sporadic group, and the follow-up time ranged from 1 to 82 months (40 months on average, median 38 months).

In total, six PCCs from four MEN 2A patients exhibited a PASS score ≥4 (ranging from 4 to 7), and these tumors were thereby classified as exhibiting “potential for aggressive behavior” (Table 1). The remaining seven tumors exhibited scores from 0 to 3. Hence, 6/13 MEN 2A-related tumors (46%) were exhibiting malignant potential by using the PASS algorithm (Fig. 1). The most prominent positive factor was the finding of large nests/diffuse growth in 10/13 PCCs (77%), followed by “high cellularity” (seen in 4/13; 31%) (Table 1). In contrast, 4/28 (14%) sporadic PCCs demonstrated PASS scores ≥4 (Fig. 1). The difference between the sporadic and MEN 2A groups was statistically significant using Fisher’s exact test (\( P = 0.049 \)) as well as the Mann-Whitney \( U \) test (\( P = 0.002 \)).

The GAPP scores ranged from 1 to 5, on an average of 2.39. Using the GAPP algorithm, seven out of 13 (54%) MEN 2A PCCs displayed GAPP scores ≥3, thereby establishing them as “moderately differentiated” with a significant risk of future relapse or metastatic disease (Table 1, Fig. 1). The remaining five MEN 2A PCCs were “well differentiated.” All PCCs with PASS scores ≥4 were also “moderately differentiated” according to GAPP (Table 1). Among the sporadic controls, 9/28 (32%) scored ≥3 whereas the majority (19/28; 68%) displayed scores below 3 and thereby classified as “well differentiated” (Fig. 1). In this group, GAPP scores ranged from 0 to 5, with an average score of 2. The difference in GAPP scores between the sporadic and MEN 2A groups was not statistically significant using Fisher’s exact test (\( P = 0.3 \)) nor the Mann-Whitney \( U \) test (\( P = 0.09 \)). Of note, 4 out of 13 (31%) MEN 2A PCCs displayed Ki-67 counts of >3% (earning two GAPP points) as compared to 3 out of 28 (11%) in the sporadic control group (Fisher’s exact test, \( P = 0.18 \)).

The mean tumor sizes were 39 and 44 mm for the MEN 2A (Table 1) and sporadic group respectively. No associations were seen between tumor size and the presence of necrosis, which could signify these parameters as independent. Moreover, no associations were seen between the patient’s \( RET \) genotype and PASS or GAPP scores (Fisher’s exact test, \( P = 0.08 \) and \( P = 0.13 \) respectively).
MEN 2A patients have an approximately 50% lifetime risk of developing PCC [1]. MEN 2A PCCs are generally benign, although few reports of malignant PCCs in the setting of MEN 2A exist, with an estimated prevalence of 3% of all tumors investigated [4]. The PASS and GAPP algorithms, despite limitations in terms of reproducibility and suboptimal specificity, represent the two histological systems suggested by the current WHO classification to stratify malignant potential in PCCs. The finding of elevated PASS and GAPP scores in approximately half of the MEN 2A PCCs is intriguing, not least given the long disease-free follow-up. Interestingly, all PCCs with PASS scores \( \geq 4 \) were also “moderately differentiated” according to GAPP, suggesting that both algorithms were concordant and most likely similarly inadequate for determining true malignant potential in MEN 2A-related PCCs.

In the original PASS publication, 8 out of 50 benign (16%) and 4 out of 50 (8%) malignant PCCs were classified as "MEN or inherited forms of pheochromocytoma" [2]. Therefore, since the vast majority of cases included were sporadic PCCs, the PASS algorithm could be suboptimal for assessing malignant potential of MEN 2A-associated cases. Regarding the GAPP algorithm, no clear-cut information

---

**Table 1** MEN 2A patient characteristics with PASS and GAPP scores

| Patient | Gender | Age at diagnosis | Tumor size (mm) | RET mutation | Follow-up time (months)* | Histological pattern | Cellularity | Comedo necrosis | Vascular or capsular invasion | Ki-67 | Catecholamine type | Total GAPP |
|---------|--------|------------------|-----------------|--------------|--------------------------|---------------------|-------------|----------------|-----------------------------|-------|-----------------|-----------|
| 1A      | M      | 24               | 29              | c.1900T>C    | 17                       | 1                   | 1           | 0             | 0                           | 2     | 0               | 4         |
| 1B      | M      | 25               | 50              | c.1900T>C    | 4                        | 0                   | 1           | 0             | 0                           | 2     | 0               | 3         |
| 2A      | F      | 41               | 40              | c.1900T>G    | +200                     | 1                   | 0           | 0             | 0                           | 1     | 0               | 2         |
| 2B      | F      | 44               | 30              | c.1900T>G    | +200                     | 0                   | 0           | 0             | 0                           | 1     | 0               | 1         |
| 3A      | M      | 41               | 50              | c.1900T>G    | +200                     | 1                   | 2           | 0             | 1                           | 0     | 0               | 5         |
| 3B      | M      | 42               | 40              | c.1900T>G    | +200                     | 1                   | 0           | 2             | 0                           | 1     | 0               | 4         |
| 4       | M      | 53               | 40              | c.1900T>G    | +200                     | 1                   | 1           | 0             | 1                           | 1     | 0               | 4         |
| 5       | F      | 45               | 30              | c.1900T>G    | +200                     | 1                   | 0           | 0             | 1                           | 0     | 0               | 2         |
| 6       | F      | 24               | 25              | c.1900T>C    | 36                       | 1                   | 1           | 0             | 0                           | 2     | 0               | 4         |
| 7       | M      | 33               | 20              | c.1900T>G    | 48                       | 1                   | 2           | 0             | 0                           | 2     | 0               | 5         |
| 8       | F      | 34               | 50              | c.1900T>G    | +200                     | 1                   | 0           | 0             | 0                           | 1     | 0               | 2         |
| 9       | F      | 45               | 70              | c.1900T>G    | 96                       | 1                   | 0           | 0             | 0                           | 0     | 0               | 1         |
| 10      | F      | 30               | 30              | c.1858T>C    | 84                       | 0                   | 1           | 0             | 0                           | 1     | 0               | 2         |

---

**Table 1** Continued

| Clinical characteristics | Pheochromocytoma of the Adrenal Gland Scaled Score (PASS)* |
|--------------------------|----------------------------------------------------------|
| Patient                  | Large nests or diffuse growth | Focal or confluent necrosis | High cellularity | Cellular mononcyt | Tumor cell spindling | Mitotic figures | Capsular invasion | Profound nuclear pleomorphism | Hyperchromasia | Total PASS |
| 1A                      | 2            | 2            | 2                  | 6               |               |               |               |               |               |               |               |
| 1B                      | 2            | 2            | 2                  | 4               |               |               |               |               |               |               |               |
| 2A                      | 2            | 2            | 1                  | 3               |               |               |               |               |               |               |               |
| 2B                      | 2            | 2            | 2                  | 0               |               |               |               |               |               |               |               |
| 3A                      | 2            | 2            | 2                  | 1               |               |               |               |               |               |               |               |
| 3B                      | 2            | 2            | 2                  | 1               | 1            | 6               |               |               |               |               |               |
| 4                       | 2            | 2            | 2                  | 3               |               |               |               |               |               |               |               |
| 5                       | 2            | 2            | 2                  | 0               |               |               |               |               |               |               |               |
| 6                       | 2            | 2            | 2                  | 6               |               |               |               |               |               |               |               |
| 7                       | 2            | 2            | 2                  | 1               | 7            |               |               |               |               |               |               |
| 8                       | 2            | 2            | 2                  | 2               |               |               |               |               |               |               |               |
| 9                       | 2            | 2            | 1                  | 3               |               |               |               |               |               |               |               |
| 10                      | 2            | 2            | 2                  | 2               |               |               |               |               |               |               |               |

None of the tumors showed atypical mitotic figures, periadrenal adipose tissue invasion or vascular invasion

*No patient had any radiological or biochemical evidence of disease at follow-up

**Discussion**

MEN 2A patients have an approximately 50% lifetime risk of developing PCC [1]. MEN 2A PCCs are generally benign, although few reports of malignant PCCs in the setting of MEN 2A exist, with an estimated prevalence of 3% of all tumors investigated [4]. The PASS and GAPP algorithms, despite limitations in terms of reproducibility and suboptimal specificity, represent the two histological systems suggested by the current WHO classification to stratify malignant potential in PCCs. The finding of elevated PASS and GAPP scores in approximately half of the MEN 2A PCCs is intriguing, not least given the long disease-free follow-up. Interestingly, all PCCs with PASS scores \( \geq 4 \) were also “moderately differentiated” according to GAPP, suggesting that both algorithms were concordant and most likely similarly inadequate for determining true malignant potential in MEN 2A-related PCCs. In the original PASS publication, 8 out of 50 benign (16%) and 4 out of 50 (8%) malignant PCCs were classified as “MEN or inherited forms of pheochromocytoma” [2]. Therefore, since the vast majority of cases included were sporadic PCCs, the PASS algorithm could be suboptimal for assessing malignant potential of MEN 2A-associated cases. Regarding the GAPP algorithm, no clear-cut information
regarding the percentage of hereditary PCCs enlisted is available, although the authors state that 13 out of the 163 samples (8%) assessed were bilateral, suggestive of hereditary disease. Therefore, it seems safe to conclude that neither the PASS nor the GAPP algorithms are primarily constructed for PCCs arising in hereditary settings.

The two most noticeable positive PASS factors in our MEN 2A cohort were "large nests/diffuse growth" and "high cellularity." In the original publication, a "large nest" was defined as three to four times the size of a normal "zellballen." Thirty percent of the benign PCCs displayed either large nests or diffuse growth, as compared to 90% of the malignant PCCs, and therefore, this parameter was weighted with a score of two points [2]. In our cohort, large nests and/or diffuse growth was observed in 77% of all MEN 2A-related PCCs. Since all our cases are thought to be benign given the absence of metastases or relapses, we believe this common phenomenon might reflect the underlying biological nature of MEN 2A-related PCCs rather than echoing a malignant phenotype. Since MEN 2A PCCs harbor RET proto-oncogene mutations and express a specific hypoxia gene expression signature [4], this common genetic profile might in theory result in distinct histological patterns for subsets of cases. Indeed, the effect of hypoxia on tumor growth patterns has been previously demonstrated [5].

The significant association between high PASS scores and MEN 2A PCCs was further substantiated when a similar connotation was seen when applying the GAPP algorithm. Of specific interest, MEN 2A PCCs regularly displayed Ki-67 indexes above 1%, making it the most commonly fulfilled GAPP criteria in the MEN 2A group. The association between elevated proliferation counts and MEN 2A PCCs could signify that Ki-67 itself is of less value when evaluating malignant potential in this subset of PCCs. However, it should be noted that high proliferative tumors might signify an alarming factor independently of the PASS and GAPP scores. Indeed, previous studies have pinpointed the prognostic value of Ki-67 staining in PCCs [6].
As a limitation, this study does not include cases with apparent malignant phenotypes (such as distant metastases), and therefore, we know little regarding the sensitivity of both methods in our material. In particular, the PASS algorithm has been previously shown to demonstrate reduced sensitivity, specificity, and high intra-observer variation, and several adjacent markers and clinical parameters have therefore been employed to improve the diagnostic accuracy of the method [7–13]. Some authors in particular advocate the use of SDHB immunohistochemistry as an additional tool to detect cases with potential for aggressive behavior. The majority (9/13) of MEN 2A-related PCCs in our cohort have been previously screened for somatic SDHB mutations, and all nine cases demonstrated wild-type sequences [14]. This would suggest that SDHB mutations are uncommonly found among MEN 2A PCCs and could therefore support the notion that the vast majority of these lesions are indeed benign—although endowed with high PASS and GAPP scores.

Managing MEN 2A patients can partly be based on the established genotype-phenotype correlation [15]. Patients harboring a mutation known to be accountable for development of PCC must be followed up lifelong regarding PCC, with biochemical evaluation at least yearly and adrenal imaging either based on positive biochemistry, or at individualized intervals. Whether a patient operated bilaterally for PCC must be followed up is a matter of discussion; most clinicians would at least check for biochemical evidence for recurrence, as the risk of relapse/metastases is not negligible. If a positive PASS and/or GAPP algorithm should alter the follow-up could be debated, certainly, a malignant potential in PCC usually is taken into account.

Although based on few cases, our observation suggests that the PASS and GAPP algorithms will yield many apparently false-positive cases when assessing MEN 2A-related PCCs. This is something practicing endocrine pathologists should be aware of, not least given the consequences for each individual patient—including lifelong vigilance for recurrences.

Acknowledgements The authors are indebted to Prof. Catharina Larsson for the related scientific discussions and to Ms. Elisabeth Anfalk for sample handling.

Authors’ contributions Stenman A, Zedenius J, and Juhlin CC: study conception and design, acquisition of data, analysis and interpretation of data, drafting of manuscript, and critical revision of manuscript.

Funding information The study was supported by grants from the Swedish Cancer Society and Karolinska Institutet.

Compliance with ethical standards All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors. Informed consent was obtained from all individual participants included in the study.

Conflict of interest The authors declare that they have no conflict of interest.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Lloyd RV, Osamura RY, Klöppel G, Rosai J (eds) (2017) WHO classification of tumours of endocrine organs, 4th edn. World Health Organization classification of tumours. International Agency for Research on Cancer, Lyon, pp 179–195
2. Thompson LD (2002) Pheochromocytoma of the Adrenal gland. Scaled Score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases. Am J Surg Pathol 26:551–566
3. Kimura N, Takayanagi R, Takizawa N, Itagaki E, Katabami T, Kakoi N, Rakugi H, Ikeda Y, Tanabe A, Nigawara T, Ito S, Kimura I, Naruse M. Pheochromocytoma Study Group in Japan (2014) Pathological grading for predicting metastasis in pheochromocytoma and paraganglioma. Endocr Relat Cancer 21:405–414
4. Welander J, Söderkvist P, Gimm O (2011) Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas. Endocr Relat Cancer 18:253–276
5. Solyanik GI, Berezetskaya NM, Bulkiewicz RJ, Kulik GI (1995) Different growth patterns of a cancer cell population as a function of its starting growth characteristics: analysis by mathematical modeling. Cell Prolif 28:263–278
6. Strong VE, Kennedy T, Al-Ahmadie H et al (2008) Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle/apoptosis gene expression analysis. Surgery 143:759–768
7. Koh J-M, Ahn SH, Kim H, Kim BJ, Sung TY, Kim YH, Hong SJ, Song DE, Lee SH (2017) Validation of pathological grading systems for predicting metastatic potential in pheochromocytoma and paraganglioma. PLoS One 12:e0187398
8. Kim KY, Kim JH, Hong AR, Seong MW, Lee KE, Kim SJ, Kim SW, Shin CS, Kim SY (2016) Disentangling of malignancy from benign pheochromocytomas/paragangliomas. PLoS One 11:e0168413
9. Kulkarni MM, Khandeparkar SG, Deshmukh SD, Karekar RR, Gaopande VL, Joshi AR, Kesari MV, Shelke RR (2016) Risk stratification in paragangliomas with PASS (pheochromocytoma of the adrenal gland scaled score) and immunohistochemical markers. J Clin Diagn Res 10:EC01–EC04
10. Agarwal A, Mehrrota PK, Jain M, Gupta SK, Mishra A, Chand G, Agarwal G, Verma AK, Mishra SK, Singh U (2010) Size of the tumor and pheochromocytoma of the adrenal gland scaled score (PASS): can they predict malignancy? World J Surg 34:3022–3028
11. Wu D, Tischler AS, Lloyd RV, DeLellis RA, de Krijger R, van Nederveen F, Nosé V (2009) Observer variation in the application
of the pheochromocytoma of the Adrenal Gland Scaled Score. Am J Surg Pathol 33:599–608
12. Eisenhofer G, Tischler AS (2014) Neuroendocrine cancer. Closing the GAPP on predicting metastases. Nat Rev Endocrinol 10:315–316
13. de Wailly P, Oragano L, Radé F, Beaulieu A, Arnault V, Levillain P, Kraimps JL (2012) Malignant pheochromocytoma: new malignancy criteria. Langenbeck’s Arch Surg 397:239–246
14. Welander J, Andreasson A, Juhlin CC, Wiseman RW, Bäckdahl M, Höög A, Larsson C, Gimm O, Söderkvist P (2014) Rare germline mutations identified by targeted next-generation sequencing of susceptibility genes in pheochromocytoma and paraganglioma. J Clin Endocrinol Metab 99:E1352–E1360
15. Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF, van Amstel H, Lips CJ, Nishisho I, Takai SI, Marsh DJ, Robinson BG, Frank-Raue K, Raue F, Xue F, Noll WW, Romei C, Pacini F, Fink M, Niederle B, Zedénius J, Nordenskjöld M, Komminoth P, Hendy GN, Mulligan LM (1996) The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA 276:1575–1579